[1]鲁海涛,赵俊功,李明华,等.人体白蛋白早期干预降低延迟溶栓后血脑屏障通透性的实验研究[J].介入放射学杂志,2011,(10):803.
　LU Hai-tao,ZHAO Jun-gong,LI Ming-hua,et al.Early intervention with human albumin to reduce the tissue plasminogen activator-mediated blood-brain barrier permeability damaged by delayed reperfusion: an experimental study in rats[J].journal interventional radiology,2011,(10):803.
点击复制

人体白蛋白早期干预降低延迟溶栓后血脑屏障通透性的实验研究()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2011年10期
页码:
803
栏目:
实验研究
出版日期:
2011-10-25

文章信息/Info

Title:

Early intervention with human albumin to reduce the tissue plasminogen activator-mediated blood-brain barrier permeability damaged by delayed reperfusion: an experimental study in rats

作者:
鲁海涛;  赵俊功;  李明华;  李永东;  张培蕾
200233 上海交通大学附属第六人民医院介入和放射诊断研究所
Author(s):
LU Hai-tao;  ZHAO Jun-gong;  LI Ming-hua;  LI Yong-dong;  ZHANG Pei-lei
Institute of Interventional and Diagnostic Radiology, the Affiliated Sixth People＇s Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200233, China
关键词:
急性脑缺血;  大脑中动脉阻塞; 　溶栓; 　人体白蛋白;  血脑屏障; 　时间窗
分类号:
Ｒ７４３
文献标志码:
A
摘要:
目的 探讨人体白蛋白早期干预对延迟溶栓所致的血脑屏障通透性的影响，为降低延迟溶栓后血管源性脑水肿的防治提供依据。方法　　　采用颈内动脉线栓法建立脑缺血模型，然后分别在脑缺血２、３、４ ｈ后拔出线栓形成脑缺血再灌注模型。１３８只体重３２０ ～ ３８０ ｇ的清洁级雄性ＳＤ大鼠被随机分为假手术组、对照组、白蛋白组和联合治疗组（白蛋白＋ｒｔＰＡ），其中假手术组３只，其余每组再分为脑缺血２、３、４ ｈ再灌注亚组，每亚组１５只。在白蛋白组、联合治疗组中，２０％人体白蛋白于大脑中动脉阻塞（ＭＣＡＯ）２ ｈ时间点经大鼠股静脉给药，剂量２．５ ｇ／ｋｇ体重。联合治疗组于各再灌注时间点拔栓后立即自大鼠股静脉注入ｒｔＰＡ，剂量１０ ｍｇ／ｋｇ。各组大鼠于ＭＣＡＯ 后２４ ｈ处死，分别行２，３，５氯化三苯基四氮唑（ＴＴＣ）染色测量梗死体积、埃文斯蓝（ＥＢ）定量检测血脑屏障（ＢＢＢ）渗漏情况以及免疫组化法检测基质金属蛋白酶９（ＭＭＰ９）的表达。结果　　　大剂量人体白蛋白早期干预显著改善了２４ ｈ后大鼠的神经功能评分， ＭＣＡＯ ３ ｈ、ＭＣＡＯ ４ ｈ白蛋白组及ＭＣＡＯ ３ ｈ联合治疗组大鼠神经功能明显好于对照组（Ｐ ＜ ０．０５）；ＭＣＡＯ ４ ｈ联合治疗组较对照组神经功能评分有所改善，但差异无统计学意义（Ｐ ＞ ０．０５）。白蛋白组、联合治疗组各缺血再灌注时间点与对照组相应时间点比较梗死体积有明显缩小，组间差异有统计学意义（Ｐ ＜ ０．０５），尤其是在ＭＣＡＯ ４ ｈ白蛋白组、联合治疗组分别较对照组下降２３％和１７．３％。脑出血转化在对照组４ ｈ 出现２例、白蛋白组４ ｈ、联合治疗组４ ｈ各１例。白蛋白组、联合治疗组各缺血再灌注时间点与对照组相应时间点比较ＥＢ含量有明显降低（Ｐ ＜ ０．０５）。与对照组相比，白蛋白组、联合治疗组的ＭＭＰ９在梗死灶边缘表达阳性细胞数显著减少。结论　　　大剂量人体白蛋白早期干预，可降低实验动物延迟溶栓后的ＢＢＢ的通透性，减小梗死体积。

参考文献/References:

[1] Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors. 2001: systematic analysis of population health data[J]. Lancet, 2006, 367: 1747 - 1757.
[2] Adams HJ, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke[J]. Stroke, 2007, 38: 1655 - 1711.
[3] Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy[J]. JAMA, 2004, 292: 1831 - 1833.
[4] Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACTⅡ study: a randomized controlled trial Prolyse in acute cerebral thromboem bolism[J]. JAMA, 1999, 282: 2003 - 2011.
[5] Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window[J]. Stroke, 2001, 32: 553 - 560.
[6] Palesch YY, Hill MD, Ryckborst KJ, et al. The ALIAS pilot trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-Ⅱ: neurologic outcome and efficacy analysis[J]. Stroke, 2006, 37: 2107 - 2114.
[7] 李永东, 赵俊功, 李明华, 等. 大剂量人体白蛋白和硫酸镁对溶栓后脑组织的保护和促进修复作用[J]. 介入放射学杂志, 2008, 17: 578 - 585.
[8] Tang J, Li YJ, Mu J, et al. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats[J]. Neurol Res, 2009, 31: 189 - 194.
[9] Strbian D, Durukan A, Pitkonen M, et al. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia[J]. Neuroscience, 2008, 153: 175 - 181.
[10] Dijkhuizen RM, Asahi M, Wu O, et al. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model[J]. Stroke, 2002, 33: 2100 - 2104.
[11] Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling[J]. Nat Med, 2001, 7: 59 - 64.
[12] Goto H, Fujisawa H, Oka F, et al. Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain[J]. J Neurotrauma, 2007, 24: 745 - 752.
[13] Wang X, Asahi M, Lo EH. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures[J]. Neurosci Lett, 1999, 274: 79 - 82.
[14] Cuadrado E, Ortega L, Hemandez-Guillamon M, et al. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release[J]. J Leukoc Biol, 2008, 84: 207 - 214.
[15] Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metallopro-teinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment[J]. Stroke, 2001, 32: 1759 - 1766.
[16] Rosell A, Ortega-Aznar A, Alvarez-Sabín J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke[J]. Stroke, 2006, 37: 1399 - 1406.
[17] Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats[J]. Stroke, 2002, 33: 831 - 836.



 

相似文献/References:

[1]李永东,赵俊功,李明华,等.大剂量人体白蛋白和硫酸镁对溶栓后脑组织的保护与促进修复作用[J].介入放射学杂志,2008,(08):578.
　LI Yongdong,ZHAO Jungong,LI Minghua,et al.Protection and repair of post－thrombolytic brain tissue with high－dose human albumin and magnesium sulfate：an experimental study[J].journal interventional radiology,2008,(10):578.

备注/Memo

备注/Memo:
收稿日期：２０１１０６１２
更新日期/Last Update: 2011-10-25